Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes

被引:5
作者
Lundholm, Michelle D. [1 ]
Bena, James [2 ]
Zhou, Keren [1 ]
Tsushima, Yumiko [3 ]
Kashyap, Sangeeta R. [1 ,4 ]
机构
[1] Cleveland Clin, Dept Endocrinol Diabet & Metab, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[3] Univ Hosp Cleveland, Dept Endocrinol, Cleveland, OH 44106 USA
[4] Weill Cornell Med, Div Endocrinol Diabet & Metab, 413 East 69th St, New York, NY 10021 USA
关键词
Type; 1; diabetes; Non-alcoholic fatty liver disease; Liver scores; Liver steatosis; Liver fibrosis; Metabolic syndrome; Obesity; SIMPLE NONINVASIVE INDEX; SIGNIFICANT FIBROSIS; STEATOHEPATITIS; EPIDEMIOLOGY; STEATOSIS; PREDICT; PIOGLITAZONE; ASSOCIATION; COMBINATION; HEPATITIS;
D O I
10.1016/j.jdiacomp.2023.108405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To investigate the prevalence and clinical risk factors for non-alcoholic fatty liver disease (NAFLD) in type 1 diabetes (T1DM) by liver scores.Methods: A retrospective, unicenter, cross-sectional analysis was performed of adults with T1DM from 2015 to 2018. Steatosis scores (hepatic steatosis index-HSI, Framingham steatosis index-FSI) and fibrosis scores (FIB-4 index, AST-to-platelet ratio index-APRI) were associated with clinical parameters.Results: We identified 447 patients, 38 & PLUSMN; 14.5 yrs, 54 % female, BMI 28 & PLUSMN; 5.9 kg/m2. Liver steatosis was prevalent at 61 % by HSI > 36 and 52 % by FSI > 23. A majority of these individuals had normal liver transaminase levels. The presence of advanced fibrosis was 4 % by APRI > 0.7 and 4 % by FIB-4 > 2.67. BMI > 25 kg/ m2 correlated with steatosis scores (P < 0.001) but not fibrosis scores. Older age (>40 yrs), hypertension, dyslipidemia, and history of cardiovascular disease were associated with steatosis markers. Only 21 % had any abdominal imaging, 2 % had hepatology referral and 1 % had a liver biopsy. Glucagon-like peptide-1 agonist was prescribed in 5 % and thiazolidinedione in 4 %.Conclusion: Liver scores indicating steatosis but not fibrosis is common in adults with T1DM with obesity and/or metabolic syndrome, and is associated with older age, hypertension, and dyslipidemia. NAFLD is underdiagnosed and under-investigated; a minority of patients have had any liver evaluation or treatment.
引用
收藏
页数:6
相关论文
共 47 条
[2]   The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement [J].
Athyros, Vasilios G. ;
Alexandrides, Theodore K. ;
Bilianou, Helen ;
Cholongitas, Evangelos ;
Doumas, Michael ;
Ganotakis, Emmanuel S. ;
Goudevenos, John ;
Elisaf, Moses S. ;
Germanidis, Georgios ;
Giouleme, Olga ;
Karagiannis, Asterios ;
Karvounis, Charalambos ;
Katsiki, Niki ;
Kotsis, Vasilios ;
Kountouras, Jannis ;
Liberopoulos, Evangelos ;
Pitsavos, Christos ;
Polyzos, Stergios ;
Rallidis, Loukianos S. ;
Richter, Dimitrios ;
Tsapas, Apostolos G. ;
Tselepis, Alexandros D. ;
Tsioufis, Konstantinos ;
Tziomalos, Konstantinos ;
Tzotzas, Themistoklis ;
Vasiliadis, Themistoklis G. ;
Vlachopoulos, Charalambos ;
Mikhailidis, Dimitri P. ;
Mantzoros, Christos .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 :17-32
[3]   The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population [J].
Bedogni, Giorgio ;
Bellentani, Stefano ;
Miglioli, Lucia ;
Masutti, Flora ;
Passalacqua, Marilena ;
Castiglione, Anna ;
Tiribelli, Claudio .
BMC GASTROENTEROLOGY, 2006, 6 (1)
[4]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[5]   New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD [J].
Boursier, Jerome ;
Guillaume, Maeva ;
Leroy, Vincent ;
Irles, Marie ;
Roux, Marine ;
Lannes, Adrien ;
Foucher, Juliette ;
Zuberbuhler, Floraine ;
Delabaudiere, Cyrielle ;
Barthelon, Justine ;
Michalak, Sophie ;
Hiriart, Jean-Baptiste ;
Peron, Jean-Marie ;
Gerster, Theophile ;
Le Bail, Brigitte ;
Riou, Jeremie ;
Hunault, Gilles ;
Merrouche, Wassil ;
Oberti, Frederic ;
Pelade, Laurence ;
Fouchard, Isabelle ;
Bureau, Christophe ;
Cales, Paul ;
de Ledinghen, Victor .
JOURNAL OF HEPATOLOGY, 2019, 71 (02) :389-396
[6]   The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage [J].
Burra, Patrizia ;
Berenguer, Marina ;
Pomfret, Elizabeth .
TRANSPLANTATION, 2019, 103 (01) :19-21
[7]   The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD [J].
Chavez, Chandani Patel ;
Cusi, Kenneth ;
Kadiyala, Sushma .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (01) :29-38
[8]   Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes [J].
Cusi, K. ;
Sanyal, A. J. ;
Zhang, S. ;
Hoogwerf, B. J. ;
Chang, A. M. ;
Jacober, S. J. ;
Bue-Valleskey, J. M. ;
Higdon, A. N. ;
Bastyr, E. J., III ;
Haupt, A. ;
Hartman, M. L. .
DIABETES OBESITY & METABOLISM, 2016, 18 :50-58
[9]   American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) [J].
Cusi, Kenneth ;
Isaacs, Scott ;
Barb, Diana ;
Basu, Rita ;
Caprio, Sonia ;
Garvey, W. Timothy ;
Kashyap, Sangeeta ;
Mechanick, Jeffrey I. ;
Mouzaki, Marialena ;
Nadolsky, Karl ;
Rinella, Mary E. ;
Vos, Miriam B. ;
Younossi, Zobair .
ENDOCRINE PRACTICE, 2022, 28 (05) :528-562
[10]   Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes [J].
Cusi, Kenneth .
HEPATOLOGY, 2019, 69 (06) :2318-2322